Early measles drug R&D kicks into gear as U.S. records record outbreak

Several companies have announced preclinical efforts to develop the first-ever measles treatment.

By Meagan Parrish • July 11, 2025

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

Simone Steiner recently joined the French company to set the stage for launch.  

By Amy Baxter • July 9, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Is biopharma dealmaking getting hot again?

With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.

By Michael Gibney • July 8, 2025

The MEK effect on cancer — a slow and steady approach to drug resistance

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

By Kelly Bilodeau • July 8, 2025

Can China sustain a surge in oncology drug innovation?

The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

By Kelly Bilodeau • July 2, 2025

AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

By Michael Gibney • July 1, 2025

CDC panel, newly remade by RFK Jr., questions vaccine evidence

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

By Delilah Alvarado • June 26, 2025

Biopharma is on edge about NIH funding cuts and what the future holds for research

Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

By Michael Gibney • June 26, 2025

After myriad failures, a new wave of ALS drugs approaches

Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

By Amy Baxter • June 25, 2025

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

By Michael Gibney • June 24, 2025

Biotech’s turning point: for every challenge, an opportunity in disguise

As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

By Michael Gibney • June 20, 2025

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

By Meagan Parrish • June 17, 2025

Can ‘reputational pull’ save biotech from pharma’s image problem?

A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

By Michael Gibney • June 12, 2025

Pharma’s wins and losses in the budget bill

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

By Amy Baxter • June 11, 2025

The biggest obesity deals of 2025 so far

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

By Amy Baxter • June 9, 2025

With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

By Michael Gibney • June 6, 2025

Biotech CEO confidence hits rock bottom amid policy shifts

A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

By Meagan Parrish • June 4, 2025

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

By Jacob Bell • June 3, 2025

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies. 

By Kelly Bilodeau • June 2, 2025

AI expertise is pharma’s next big hiring need — here’s what companies should look for

The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge. 

By Alexandra Pecci • May 29, 2025

Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

By Jacob Bell • May 28, 2025

With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

By Michael Gibney • May 28, 2025

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

By Amy Baxter • May 21, 2025

The placebo effect: How a new FDA rule could pile more strain onto vaccine developers

The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.

By Alexandra Pecci • May 20, 2025

A startup with Theranos ties has another blood test in the works. This time, competition is waiting.

A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.

By Meagan Parrish • May 16, 2025